This Article Full Text Full Text (PDF) All Versions of this Article: 53/4/587    most recent HYPERTENSIONAHA.108.125922v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wenzel, P. Articles by Münzel, T. Search for Related Content PubMed PubMed Citation Articles by Wenzel, P. Articles by Münzel, T. Related Collections Hypertension - basic studies Related Article

(Hypertension. 2009;53:587.)
© 2009 American Heart Association, Inc.

Editorial Commentaries

From Menace to Marvel

High-Density Lipoprotein Prevents Endothelial Nitric Oxide Synthase Uncoupling in Diabetes Mellitus by Angiotensin II Type 1 Receptor Downregulation

Philip Wenzel; Thomas Münzel

From the II Medizinische Klinik der Johannes-Gutenberg-Universität Mainz, Mainz, Germany.

Correspondence to Thomas Münzel, II Medizinische Klinik, Johannes Gutenberg-Universität Mainz, Langenbeckstr 1, 55131 Mainz, Germany. E-mail tmuenzel@uni-mainz.de

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Diabetes mellitus is a major risk factor for cardiovascular disease, and its prevalence is suspected to further increase in the coming years in the Western hemisphere and also in countries with emerging economies, like India, China, and Brazil. Together with the increasing prevalence of obesity and metabolic syndrome and the subsequent development of arterial hypertension, the epidemic of adiposity and diabetes mellitus may eat up most of the improvement of cardiovascular outcomes that we have seen within the last decades.¹

The risk of atherosclerosis is inversely related to circulating levels of high-density lipoprotein (HDL) cholesterol. Results from the Framingham Study demonstrated that this association is independent of low-density lipoprotein. Clinical trials using agents (eg, fibrates) that increase HDL have been shown to decrease cardiovascular event rates. On the other hand, therapy with the HDL-raising substance torcetrapib is associated with increased cardiovascular events, although the mechanism for this remains unclear and is probably independent of the effects on HDL cholesterol.²

The classical function of HDL is the so called "reverse cholesterol transport" removing cholesterol from peripheral tissue and delivering it to the liver by binding of the major HDL apolipoprotein (apo), apoA-I, to the HDL receptor scavenger receptor B type I. Intra-arterial infusion of apoA-I/phosphatidylcholine in hypercholesterolemic patients with normal HDL improves endothelial dysfunction, suggesting that HDL is a positive modulator of vascular NO bioavailability. Infusion of reconstituted HDL even leads to acute changes in human atherosclerotic plaque composition characterized by a reduction in lipid content within the atherosclerotic plaque.³

With . . . [Full Text of this Article]

Related Article:

Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor

Sophie Van Linthout, Frank Spillmann, Mario Lorenz, Marco Meloni, Frank Jacobs, Marina Egorova, Verena Stangl, Bart De Geest, Heinz-Peter Schultheiss, and Carsten Tschöpe
Hypertension 2009 53: 682-687. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				C. Marchesi, T. Ebrahimian, O. Angulo, P. Paradis, and E. L. Schiffrin Endothelial Nitric Oxide Synthase Uncoupling and Perivascular Adipose Oxidative Stress and Inflammation Contribute to Vascular Dysfunction in a Rodent Model of Metabolic Syndrome Hypertension, December 1, 2009; 54(6): 1384 - 1392. [Abstract] [Full Text] [PDF]